The rising rate of admissions for tonsillitis and neck space abscesses in England, 1991-2011

Annals of The Royal College of Surgeons of England (Impact Factor: 1.27). 05/2014; 96(4):307-310. DOI: 10.1308/003588414X13946184900363
Source: PubMed


Sore throats and tonsillitis represent a considerable health burden as well as a significant source of expenditure for the National Health Service (NHS). As part of the recent NHS savings drive, the introduction of 'procedures of low clinical effectiveness' (PoLCE) lists has reinforced a large reduction in the number of tonsillectomies performed. We carried out a cross-sectional study of trends in emergency sore throat admissions in the context of the number of tonsillectomies performed.
Hospital Episode Statistics (HES) data were extracted. Office for National Statistics data were also used.
Between 1991 and 2011, the overall tonsillectomy rate fell by 44%. In the same time, the admission rate for tonsillitis rose by 310% (Pearson's r=-0.67, p=0.01). The peritonsillar abscess admission rate rose by 31% (r=-0.79, p<0.01). Between 1996 and 2011, the overall tonsillectomy rate fell by 41% and the retro and parapharyngeal abscess admission rate rose by 39% (r=-0.55, p=0.026). There was a 14% overall increase in tonsillectomy and sore throat associated bed days. This was despite the large fall in tonsillectomy numbers and the reduction in length of hospital stay.
Efforts to reduce the tonsillectomy rate are correlated with a significant rise in emergency admissions. The rise in the retro and parapharyngeal abscess rate is perhaps most alarming given the very high mortality of these conditions. Bed day data suggest that no net saving has been made despite the new measures.

Download full-text


Available from: Andrew S Lau, Oct 13, 2014
1 Follower
48 Reads
  • Source
    • "The Paradise study [2] became the adopted standard in whole or in part of many clinical guidelines throughout the world [3] [4] [5] [6]. The Lau study [1] shows that the reduction in the operative intervention, at least the United Kingdom, has resulted in an increase in morbidity which should have been avoided. The analysis [7] of randomized controlled studies examining tonsillar pharyngitis has shown that they have severe limitations and at best are only applicable to narrowly defined and highly circumscribed populations. "
    International Journal of Pediatric Otorhinolaryngology 11/2014; 79(1). DOI:10.1016/j.ijporl.2014.11.013 · 1.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unlabelled: Controversy remains about the need for antibiotic therapy of group A streptococcal (GAS) pharyngitis in high-resource settings. Guidelines on the management of GAS pharyngitis differ considerably, especially in children. We performed a literature search on the diagnosis and treatment of GAS pharyngitis in children and compared different guidelines with current epidemiology and the available evidence on management. Some European guidelines only recommend antibiotic treatment in certain high-risk patients, while many other, including all American, still advise antimicrobial treatment for all children with GAS pharyngitis, given the severity and re-emerging incidence of complications. Empirical antimicrobial treatment in children with sore throat and a high clinical suspicion of GAS pharyngitis will still result in significant overtreatment of nonstreptococcal pharyngitis. This is costly and leads to emerging antibiotic resistance. Early differential diagnosis between viral and GAS pharyngitis, by means of a 'rapid antigen detection test' (RADT) and/or a throat culture, is therefore needed if 'pro treatment' guidelines are used. Conclusion: Large scale randomized controlled trials are necessary to assess the value of antibiotics for GAS pharyngitis in high-resource countries, in order to achieve uniform and evidence-based guidelines. The severity and the possibly increasing incidence of complications in school-aged children suggests that testing and treating proven GAS pharyngitis can still be beneficial.
    European Journal of Pediatrics 08/2014; 173(10). DOI:10.1007/s00431-014-2395-2 · 1.89 Impact Factor
  • Canadian Medical Association Journal 12/2014; 187(1). DOI:10.1503/cmaj.141532 · 5.96 Impact Factor
Show more